Antibodies to oxidized low density lipoprotein: Epidemiological studies and potential clinical applications in cardiovascular disease

Minerva Cardioangiologica

Volumn 55, Issue 6, 2007, Pages 821-837

  Gounopoulos, P ^a   Merki, E ^a   Hansen, L F ^a   Choi, S H ^a   Tsimikas, S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Cardiovascular diseases; LDL; Lipoproteins

Indexed keywords

ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOAM CELL; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATION; REVIEW;

ADULT; AGED; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITOPES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MICE; MIDDLE AGED; ODDS RATIO; OXIDATION-REDUCTION; OXIDATIVE STRESS; RABBITS; RISK FACTORS; VACCINATION;

EID: 38649095192     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Glass CK, Witztum JL. Atherosclerosis, the road ahead. Cell 2001;104:503-16.
2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low-density lipoprotein that Increase its atherogenicity. New Engl J Med 1989;320:915-24.
4. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982;31:283-91.
5. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci U S A 1984;81:3204-8.
6. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 1984;25:1109-16.
7. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989;86:1372-6.
8. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
9. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002;16:1348-60.
10. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1569-76.
11. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:95-100.
12. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-60.
13. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002;22:1649-54.
14. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999;6:41-53.
15. Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 2004;24:2307-12.
16. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis. An appraisal [In Process Citation]. J Lipid Res 1999;40:2143-57.
17. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-35.
18. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000;247:371-80.
19. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-26.
20. Hansson GK. ATVB In Focus: Immunity and Atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:17.
21. Virella G, Lopes-Virella MF. Lipoprotein autoantibodies: Measurement and significance. Clin Diagn Lab Immunol 2003;10:499.
22. Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 2006;47:2436-43.
23. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 2006;47:1803-10.
24. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP et al. Relationship of IgM and IgG autoantibodies to oxidized low density lipoprotein and apolipoprotein B100-immune complexes with angiographically determined coronary artery disease and cardiovascular events. J Lipid Res 2006.
25. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999;90:165-72.
26. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000;148:171-7.
27. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110:1406-12.
28. Tsimikas S. Measures of oxidative stress. Clin Lab Med 2006;26:571-90.
29. Reardon CA, Miller ER, Blachowicz L, Lukens J, Binder CJ, Witztum JL et al. Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. J Lipid Res 2004;45:1347-54.
30. Lourida ES, Georgiadis AN, Papavasiliou EC, Papathanasiou AI, Drosos AA, Tselepis AD. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res Ther 2007;9:R19.
31. Papathanasiou AI, Lourida ES, Tsironis LD, Goudevenos JA, Tselepis AD. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes Role of the lipoprotein-associated phospholipase A(2) and the effect of atorvastatin treatment. Atherosclerosis 2006.
32. Lourida ES, Papathanasiou AI, Goudevenos JA, Tselepis AD. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 2006;75:117-26.
33. Parums O, Mitchinson MJ. Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Arteriosclerosis 1981;38:211-6.
34. Hansson GK, Bondjers G, Bylock A, Hjalmarsson L. Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits. Exp Mol Pathol 1980;33:302-15.
35. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989;135:815-25.
36. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;241:215-8.
37. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990;10:336-49.
38. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994;14:605-16.
39. Jürgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb 1993;13:1689-99.
40. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
41. Boullier A, Gillotte KL, Hörkkö S, Green SR, Friedman P, Dennis EA et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000;275:9163-9.
42. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995;36:2320-8.
43. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999;103:1597-604.
44. Cyrus T, Praticó D, Zhao L, Witztum JL, Rader DJ, Rokach J et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation 2001;103:2277-82.
45. Pratico D, Tangirala RK, Horkko S, Witztum JL, Palinski W, FitzGerald GA. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation bv vitamin E. Blood 2001;97:459-64.
46. Iughetti L, Volta C, Maggi E, Palladini G, Perugini C, Bellomo G et al. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr Res 1999;45:94-9.
47. Tinahones FJ, Mez-Zumaquero JM, Rojo M, Cardona F, de Antonio IE, de Adana MSR et al. Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population. Metabolism 2002;51:429-31.
48. Fredrikson GN, Hedblad B, Berglund G, Alm R, Ares M, Cercek B et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23:872-8.
49. Steinerova A, Stozicky F, Racek J, Tatzber F, Zima T, Setina R. Antibodies against oxidized LDL in infants. Clin Chem 2001;47:1137-8.
50. Wilson PWF, Ben Yehuda O, McNamara J, Massaro J, Witztum JL, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. Atherosclerosis 2006;189:364-8.
51. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J 1996;131:663-7.
52. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001;37:775-9.
53. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-7.
54. Luoma JS, Kareinen A, Narvanen O, Viitanen L, Laakso M, Yla-Herttuala S. Autoantibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease. Free Radical Biology and Medicine 2005;39:1660-5.
55. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating Immune Complexes in 50-Year-Old Men as a Strong and Independent Risk Factor for Myocardial Infarction. Circulation 2000;102:2576-81.
56. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-63.
57. Erkkila AT, Narvanen O, Lento S, Uusitupa MI, Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:204-9.
58. Bouffier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart JC et al. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta 1995;238:1-10.
59. Rossi GP, Cesari M, De Toni R, Zanchetta M, Maiolino G, Pedon L et al. Antibodies to oxidized Low-Density Lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 2003;108:2467-72.
60. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:1236-42.
61. van de Vijver LPL, Steyger R, van Poppel G, Boer JMA, Kruijssen DACM, Seidell JC et al. Autoantibodies against MDA-LDL in subjects with severe and minor athero-sclerosis and healthy population controls. Atherosclerosis 1996;122:245-53.
62. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
63. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994;14:1892-9.
64. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001;21:101-7.
65. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies aainst oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000;20:703-7.
66. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007.
67. Karvonen J, Paivansalo M, Kesaniemi YA, Hörkkö S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003;108:2107-12.
68. Goncalves I, Gronholdt ML, Soderberg I, Ares MPS, Nordestgaard BG, Bentzon JF et al. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler Thromb Vasc Biol 2005;25:1250-5.
69. Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 2007;38:1495-500.
70. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003;23:879-84.
71. Binder CJ, Shaw PX, Chang MK, Bouffier A, Hartvigsen K, Horkko S et al. Thematic review series: The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis. Journal of Lipid Research 2005;46:1353-63.
72. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-9.
73. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-70.
74. Schumacher M, Eber B, Tatzber F, Kaufmann P, Halwachs G, Fruhwald FM et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 1995;18:1087-91.
75. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004;109:3164-70.
76. Orem C, Orem A, Uydu HA, Celik S, Erdol C, Kural BV. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 2002;13:65-71.
77. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. British Journal of Clinical Pharmacology 2006;61:262-74.
78. Binder CJ, Silverman GJ. Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol 2005;26:385-404.
79. Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005;26:347-62.
80. Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007;117:712-8.
81. Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, Horkko S et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005.
82. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912-6.
83. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003;108:2034-40.
84. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002;22:1892-8.
85. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002;109:745-53.
86. Chang MK, Bergmark C, Laurila A, Hörkkö S, Han KH, Friedman P et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A 1999;96:6353-8.
87. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Nad Acad Sci U S A 2002;99:13043-8.
88. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, Berliner JA et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004;200:1359-70.
89. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
90. -/- Mice. J Clin Invest 1997;100:1575-80.
91. Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 2001;42:1474-82.
92. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999;103:117-28.
93. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996;98:800-14.
94. Shaw PX, Hörkkö S, Chang MK, Curtiss LK, Palinski W, Silverman GJ et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-40.
95. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982;156:1177-85.
96. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-91.
97. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003;9:736-43.
98. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992;12:789-99.
99. Cowden J, Parker SK. Monoclonal antibodies: production, uses and side effects. Pediatr Infect Dis J 2006;25:553-5.
100. Palinski W, Miller E, Witztum JL. Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995;92:821-5.
101. Nilsson J, Calara F, Regnstrom J, Hultgardh-Nilsson A, Ameli S, Cercek B et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1997;30:1886-91.
102. Freigang S, Hörkkö S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde- modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998;18:1972-82.
103. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL Immunization Induces T-Cell-Dependent Antibody Formation and Protection Against Atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:108-14.
104. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996;16:1074-9.
105. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004;114:427-37.
106. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C et al. Phosphorylcholine-Targeting Immunization Reduces Atherosclerosis. Journal of the American College of Cardiology 2007;50:540-6.
107. Binder CJ, Hartvigsen K, Witztum JL. Promise of Immune Modulation to Inhibit Atherogenesis. Journal of the American College of Cardiology 2007;50:547-50.
108. Chyu KY, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano J et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun 2005;338:1982-9.
109. Fredrikson GN, Lindholm MW, Ljungcrantz I, Soderberg I, Shah PK, Nilsson J. Autoimmune responses against the apo B-100 LDL receptor-binding site protect against arterial accumulation of lipids in LDL receptor deficient mice. Autoimmunity 2007;40:122-30.
110. van Puijvelde GH, Hauer AD, de Vos P, van den HR, van Herwijnen MJ, van der ZR et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006;114:1968-76.
111. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998;102:910-8.
112. Nicolo D, Goldman BI, Monestier M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003;48:2974-8.
113. Schiopu A, Bengtsson J, Soderberg I, Janciauskiene S, Lindgren S, Ares MP et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004;110:2047-52.
114. Strom A, Fredrikson GN, Schiopu A, Ljungcrantz I, Soderberg I, Jansson B et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 2007;190:298-305.
115. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, Yano J et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein Å-null mice. Atherosclerosis 2006;189: 83-90.
116. Shaw PX, Hörkkö S, Tsimikas S, Chang MK, Palinski W, Silverman GJ et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001;21:1333-9.
117. -/- mice. Arterioscler Thromb Vasc Biol 2007;e97.
118. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development - clinical and animal studies. Clinica Chimica Acta 2004;348:1-8.
119. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are antioxidized Low-Density Lipoprotein antibodies pathogenic or protective? Circulation 2004;110:2552-8.